These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9523729)

  • 1. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection.
    Embree L; Gelmon K; Tolcher A; Hudon N; Heggie J; Dedhar C; Logan P; Bally MB; Mayer LD
    Cancer Chemother Pharmacol; 1998; 41(5):347-52. PubMed ID: 9523729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients.
    Bedikian AY; Vardeleon A; Smith T; Campbell S; Namdari R
    J Clin Pharmacol; 2006 Jul; 46(7):727-37. PubMed ID: 16809798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic characteristics of vincristine sulfate liposomes in patients with advanced solid tumors.
    Yan Z; Zhu ZL; Qian ZZ; Hu G; Wang HQ; Liu WH; Cheng G
    Acta Pharmacol Sin; 2012 Jun; 33(6):852-8. PubMed ID: 22669119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates.
    Shah NN; Cole DE; Lester-McCully CM; Wayne AS; Warren KE; Widemann BC
    Invest New Drugs; 2016 Feb; 34(1):61-5. PubMed ID: 26661090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia.
    Silverman JA; Reynolds L; Deitcher SR
    J Clin Pharmacol; 2013 Nov; 53(11):1139-45. PubMed ID: 23907766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of a high-performance liquid chromatographic assay method for quantification of total vincristine sulfate in human plasma following administration of vincristine sulfate liposome injection.
    Embree L; Gelmon KA; Tolcher AW; Hudon NJ; Heggie JR; Dedhar C; Webb MS; Bally MB; Mayer LD
    J Pharm Biomed Anal; 1997 Dec; 16(4):675-87. PubMed ID: 9502163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma.
    Yang F; Jiang M; Lu M; Hu P; Wang H; Jiang J
    Front Pharmacol; 2018; 9():991. PubMed ID: 30210349
    [No Abstract]   [Full Text] [Related]  

  • 8. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties.
    Krishna R; Webb MS; St Onge G; Mayer LD
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1206-12. PubMed ID: 11504822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of free and total vincristine in human plasma after intravenous administration of vincristine sulfate liposome injection using ultra-high performance liquid chromatography tandem mass spectrometry.
    Yang F; Wang H; Liu M; Hu P; Jiang J
    J Chromatogr A; 2013 Feb; 1275():61-9. PubMed ID: 23294995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of liposomal vincristine.
    Gelmon KA; Tolcher A; Diab AR; Bally MB; Embree L; Hudon N; Dedhar C; Ayers D; Eisen A; Melosky B; Burge C; Logan P; Mayer LD
    J Clin Oncol; 1999 Feb; 17(2):697-705. PubMed ID: 10080616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias.
    Shah NN; Merchant MS; Cole DE; Jayaprakash N; Bernstein D; Delbrook C; Richards K; Widemann BC; Wayne AS
    Pediatr Blood Cancer; 2016 Jun; 63(6):997-1005. PubMed ID: 26891067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function.
    Bedikian AY; Silverman JA; Papadopoulos NE; Kim KB; Hagey AE; Vardeleon A; Hwu WJ; Homsi J; Davies M; Hwu P
    J Clin Pharmacol; 2011 Aug; 51(8):1205-12. PubMed ID: 20978276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine.
    Silverman JA; Deitcher SR
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):555-64. PubMed ID: 23212117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma.
    Bedikian AY; Papadopoulos NE; Kim KB; Vardeleon A; Smith T; Lu B; Deitcher SR
    Melanoma Res; 2008 Dec; 18(6):400-4. PubMed ID: 19011511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose vincristine sulfate liposome injection (Marqibo) Is not associated with clinically meaningful hematologic toxicity.
    Deitcher OR; Glaspy J; Gonzalez R; Sato T; Bedikian AY; Segarini K; Silverman J; Deitcher SR
    Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):197-202. PubMed ID: 24417913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents.
    Frost BM; Lönnerholm G; Koopmans P; Abrahamsson J; Behrendtz M; Castor A; Forestier E; Uges DR; de Graaf SS
    Acta Paediatr; 2003 May; 92(5):551-7. PubMed ID: 12839283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.
    O'Brien S; Schiller G; Lister J; Damon L; Goldberg S; Aulitzky W; Ben-Yehuda D; Stock W; Coutre S; Douer D; Heffner LT; Larson M; Seiter K; Smith S; Assouline S; Kuriakose P; Maness L; Nagler A; Rowe J; Schaich M; Shpilberg O; Yee K; Schmieder G; Silverman JA; Thomas D; Deitcher SR; Kantarjian H
    J Clin Oncol; 2013 Feb; 31(6):676-83. PubMed ID: 23169518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of liposomal-encapsulated and un-encapsulated vincristine after injection of liposomal vincristine sulfate in beagle dogs.
    Zhong J; Mao W; Shi R; Jiang P; Wang Q; Zhu R; Wang T; Ma Y
    Cancer Chemother Pharmacol; 2014 Mar; 73(3):459-66. PubMed ID: 24362508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
    Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas.
    Hagemeister F; Rodriguez MA; Deitcher SR; Younes A; Fayad L; Goy A; Dang NH; Forman A; McLaughlin P; Medeiros LJ; Pro B; Romaguera J; Samaniego F; Silverman JA; Sarris A; Cabanillas F
    Br J Haematol; 2013 Sep; 162(5):631-8. PubMed ID: 23802738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.